Simone de Brot
University of Nottingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Simone de Brot.
Endocrine-related Cancer | 2015
Simone de Brot; Atara Ntekim; Ryan Cardenas; Victoria James; Cinzia Allegrucci; David M. Heery; David O Bates; Niels Ødum; Jenny L Persson; Nigel P Mongan
Prostate cancer (PCa) is the most common malignancy affecting men in the western world. Although radical prostatectomy and radiation therapy can successfully treat PCa in the majority of patients, up to ~30% will experience local recurrence or metastatic disease. Prostate carcinogenesis and progression is typically an androgen-dependent process. For this reason, therapies for recurrent PCa target androgen biosynthesis and androgen receptor function. Such androgen deprivation therapies (ADT) are effective initially, but the duration of response is typically ≤24 months. Although ADT and taxane-based chemotherapy have delivered survival benefits, metastatic PCa remains incurable. Therefore, it is essential to establish the cellular and molecular mechanisms that enable localized PCas to invade and disseminate. It has long been accepted that metastases require angiogenesis. In the present review, we examine the essential role for angiogenesis in PCa metastases, and we focus in particular on the current understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and metastatic PCa. We highlight recent advances in understanding the role of VEGF in regulating the interaction of cancer cells with tumor-associated immune cells during the metastatic process of PCa. We summarize the established mechanisms of transcriptional and post-transcriptional regulation of VEGF in PCa cells and outline the molecular insights obtained from preclinical animal models of PCa. Finally, we summarize the current state of anti-angiogenesis therapies for PCa and consider how existing therapies impact VEGF signaling.
BMC Veterinary Research | 2015
Chloé Monthoux; Simone de Brot; Michelle Amanada Jackson; U. Bleul; Jasmin Walter
BackgroundSkin malformations that resembled manifestations of Ehlers-Danlos-Syndrome were described in a variety of domestic animals during the last century as cutis hyperelastica, hyperelastosis cutis, dermatosparaxis, dermal/collagen dysplasia, dermal/cutaneous asthenia or Ehlers-Danlos-like syndrome/s. In 2007, the mutation responsible for Hereditary Equine Regional Dermal Asthenia (HERDA) in Quarter Horses was discovered. Several case reports are available for similar malformations in other breeds than Quarter Horses (Draught Horses, Arabians, and Thoroughbreds) including four case reports for Warmblood horses. Since 2013, a genetic test for the Warmblood Fragile Foal Syndrome Type 1 (WFFS), interrogating the causative point mutation in the equine procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1, or lysyl hydroxylase 1) gene, has become available. Only limited data are available on the occurrence rate and clinical characteristics of this newly detected genetic disease in horses. In humans mutations in this gene are associated with Ehlers-Danlos Syndrome Type VI (kyphoscoliotic form).Case presentationThis is the first report describing the clinical and histopathological findings in a foal confirmed to be homozygous positive for WFFS. The Warmblood filly was born with very thin, friable skin, skin lesions on the legs and the head, and an open abdomen. These abnormalities required euthanasia just after delivery. Histologic examination revealed abnormally thin dermis, markedly reduced amounts of dermal collagen bundles, with loosely orientation and abnormally large spaces between deep dermal fibers.ConclusionWFFS is a novel genetic disease in horses and should be considered in cases of abortion, stillbirth, skin lesions and malformations of the skin in neonatal foals. Genetic testing of suspicious cases will contribute to evaluate the frequency of occurrence of clinical WFFS cases and its relevance for the horse population.
Placenta | 2017
Veronika M. Metzler; Simone de Brot; R.S. Robinson; Jennie N. Jeyapalan; Emad A. Rakha; Thomas J. Walton; David S. Gardner; Emma F. Lund; Jonathan Whitchurch; Daisy Haigh; Jack M. Lochray; Brian D. Robinson; Cinzia Allegrucci; Rupert G. Fray; Jenny L. Persson; Niels Ødum; Regina Miftakhova; Albert A. Rizvanov; Ieuan A. Hughes; Rieko Tadokoro-Cuccaro; David M. Heery; Catrin S. Rutland; Nigel P. Mongan
The placenta and tumors share important characteristics, including a requirement to establish effective angiogenesis. In the case of the placenta, optimal angiogenesis is required to sustain the blood flow required to maintain a successful pregnancy, whereas in tumors establishing new blood supplies is considered a key step in supporting metastases. Therefore the development of novel angiogenesis inhibitors has been an area of active research in oncology. A subset of the molecular processes regulating angiogenesis are well understood in the context of both early placentation and tumorigenesis. In this review we focus on the well-established role of androgen regulation of angiogenesis in cancer and relate these mechanisms to placental angiogenesis. The physiological actions of androgens are mediated by the androgen receptor (AR), a ligand dependent transcription factor. Androgens and the AR are essential for normal male embryonic development, puberty and lifelong health. Defects in androgen signalling are associated with a diverse range of clinical disorders in men and women including disorders of sex development (DSD), polycystic ovary syndrome in women and many cancers. We summarize the diverse molecular mechanisms of androgen regulation of angiogenesis and infer the potential significance of these pathways to normal and pathogenic placental function. Finally, we offer potential research applications of androgen-targeting molecules developed to treat cancer as investigative tools to help further delineate the role of androgen signalling in placental function and maternal and offspring health in animal models.
American Journal of Physiology-renal Physiology | 2016
David S. Gardner; Simone de Brot; Louise J. Dunford; L. Grau-Roma; Simon J. M. Welham; Rebecca Fallman; Saoirse E O'Sullivan; Weng Oh; Mark Devonald
Acute kidney injury (AKI) is a common and serious condition with no specific treatment. An episode of AKI may affect organs distant from the kidney, further increasing the morbidity associated with AKI. The mechanism of organ cross talk after AKI is unclear. The renal and immune systems of pigs and humans are alike. Using a preclinical animal (porcine) model, we tested the hypothesis that early effects of AKI on distant organs is by immune cell infiltration, leading to inflammatory cytokine production, extravasation, and edema. In 29 pigs exposed to either sham surgery or renal ischemia-reperfusion (control, n = 12; AKI, n = 17), we assessed remote organ (liver, lung, brain) effects in the short (from 2- to 48-h reperfusion) and longer term (5 wk later) using immunofluorescence (for leukocyte infiltration, apoptosis), a cytokine array, tissue elemental analysis (e.g., electrolytes), blood hematology and chemistry (e.g., liver enzymes), and PCR (for inflammatory markers). AKI elicited significant, short-term (∼24 h) increments in enzymes indicative of acute liver damage (e.g. , AST: ALT ratio; P = 0.02) and influenced tissue biochemistry in some remote organs (e.g., lung tissue [Ca(2+)] increased; P = 0.04). These effects largely resolved after 48 h, and no further histopathology, edema, apoptosis, or immune cell infiltration was noted in the liver, lung, or hippocampus in the short and longer term. AKI has subtle biochemical effects on remote organs in the short term, including a transient increment in markers of acute liver damage. These effects resolved by 48 h, and no further remote organ histopathology, apoptosis, edema, or immune cell infiltration was noted.
Oncology Letters | 2018
Simone de Brot; Brian D. Robinson; Tim Scase; Llorenç Grau‑Roma; Eleanor Wilkinson; Stephen A. Boorjian; David S. Gardner; Nigel P. Mongan
Despite the recent approval of several novel agents for patients with metastatic urothelial carcinoma (UC), survival in this setting remains poor. As such, continued investigation into novel therapeutic options remains warranted. Pre-clinical development of novel treatments requires an animal model that accurately simulates the disease in humans. The aim of the present study was to evaluate the dog as an animal model for human UC. A total of 260 cases of spontaneous, untreated canine primary urethral and urinary bladder UC, were epidemiologically and histologically assessed and classified based on the current 2016 World Health Organization (WHO) tumor classification system. Canine data was compared with human data available from scientific literature. The mean age of dogs diagnosed with UC was 10.22 years (range, 4–15 years), which is equivalent to 60–70 human years. The results revealed a high association between UC diagnosis with the female sex [odds ratio (OR) 3.51; 95% confidence interval (CI) 2.57–4.79; P<0.001], surgical neutering (OR 4.57; 95% CI 1.87–11.12; P<0.001) and breed (OR 15.11 for Scottish terriers; 95% CI 8.99–25.41; P<0.001). Based on the 2016 WHO tumor (T), node and metastasis staging system, the primary tumors were characterized as T1 (38%), T2a (28%), T2b (13%) and T3 (22%). Non-papillary, flat subgross tumor growth was strongly associated with muscle invasion (OR 31.00; P<0.001). Irrespective of subgross growth pattern, all assessable tumors were invading beyond the basement membrane compatible with infiltrating UC. Conventional, not further classifiable infiltrating UC was the most common type of tumor (90%), followed by UC with divergent, squamous and/or glandular differentiation (6%). Seven out of the 260 (2.8%) cases were classified as non-urothelial based on their histological morphology. These cases included 5 (2%) squamous cell carcinomas, 1 (0.4%) adenocarcinoma and 1 (0.4%) neuroendocrine tumor. The 2 most striking common features of canine and human UC included high sex predilection and histological tumor appearance. The results support the suitability of the dog as an animal model for UC and confirm that dogs also spontaneously develop rare UC subtypes and bladder tumors, including plasmacytoid UC and neuroendocrine tumor, which are herein described for the first time in a non-experimental animal species.
Laryngoscope Investigative Otolaryngology | 2018
Rishie Sinha; Ricardo Correia; David S. Gardner; L. Grau-Roma; Simone de Brot; J.G. Hardman; Steve Morgan; Andrew Norris
Postintubation laryngotracheal injury is common. Assessment of histopathological changes currently requires animal models. We set about developing a viable, resource effective animal model to study these effects and to develop a detailed tissue injury score.
Journal of Feline Medicine and Surgery Open Reports | 2018
Cécile Dor; Jessica L Adamany; Caroline Kisielewicz; Simone de Brot; Kerstin Erles; Marc P Dhumeaux
Case summary A 5-year-old male neutered Persian cat was referred for investigation of a 4 week history of weight loss, inappetence and intermittent vomiting. Chronic kidney disease (CKD) and inflammatory bowel disease were diagnosed, and despite immunosuppressive therapy and assisted enteral nutrition, the cat experienced persistent anorexia, vomiting and severe weight loss. After 2 additional weeks of treatment, the cat developed acute-onset neurological signs associated with severe hyperammonaemia and was euthanased. Plasma amino acid assessment revealed deficiency of several amino acids involved in the urea cycle, including arginine. Relevance and novel information To our knowledge, this is the first reported case of an acquired urea cycle amino acid deficiency without nutritional deprivation in a cat. Several contributing factors were suspected, including intestinal malabsorption and CKD. This case demonstrates the importance of urea cycle amino acids in feline metabolism and possible necessity for parenteral supplementation, particularly in the context of persistent weight loss despite adequate enteral nutrition.
Cancer and Noncoding RNAs | 2018
Simone de Brot; Catrin S. Rutland; Nigel P. Mongan; Victoria James
Abstract MicroRNAs (miRNAs or miRs) are involved in pathways central to homeostasis and cellular function, including proliferation, differentiation, and apoptosis; processes which when aberrantly regulated contribute to the hallmarks of cancer. The contribution of miRNAs to normal cellular function is often context dependent and the same is true of miRNA function in cancer; with the action of miRNAs as oncomiRs or tumor suppressor miRs often being dependent upon the tissue type and the cellular context of their expression. Alteration of miRNA expression via mutations and epigenetic modification is frequently seen in cancer at both early and more progressive stages. In this chapter, we will discuss the altered pattern of epigenetic regulation of miRNAs and their regulatory machinery as well as the potential impact of epigenetic drugs.
Cancer and Noncoding RNAs | 2018
Catrin S. Rutland; Simone de Brot; Victoria James; Nigel P. Mongan
Abstract In eukaryotes, the packaging of DNA and proteins, termed chromatin, is an essential determinant of transcription. The basic unit of chromatin, the nucleosome, is composed of ∼146 base pairs of DNA spooled around a dense protein core containing two copies each of histones H2A, H2B, H3, and H4. These histone proteins are highly conserved and possess tails, which extend and interact with DNA. Covalent modifications that alter the charge of the histone tail are believed to influence their electrostatic interaction with DNA and act as interaction surfaces for epigenetic effectors that influence the level of chromatin compaction and accessibility to the transcriptional apparatus. Less-compacted chromosomal regions, euchromatin, tend to be gene rich and transcriptionally active. In contrast, condensed constitutive heterochromatin plays an essential function in chromosomal integrity and structural regions such as the centromere and telomere. Facultative heterochromatin plays an essential role by imposing the differentiation-specific transcriptional regulation required to underpin cellular identity. Long noncoding RNAs (lncRNAs) are emerging as key transcriptional regulators, which cooperate with the polycomb repressive complexes and the heterochromatin apparatus in differentiation. Unsurprisingly, disruption of this key pathway is now recognized to play important roles in carcinogenesis and metastases. In this chapter, we review current understanding of the normal and oncogenic functions of lncRNAs, polycomb, and heterochromatin.
Avian Pathology | 2017
L. Grau-Roma; Kirsty Reid; Simone de Brot; Richard Jennison; Paul A. Barrow; Raúl Sánchez; Miquel Nofrarías; Michael Clark; Natàlia Majó
ABSTRACT Increasing evidence suggests that a new birnavirus, named chicken proventricular necrosis virus (CPNV), is the aetiological agent of transmissible viral proventriculitis (TVP). The present work aimed to explore the possible presence of both TVP and CPNV in the UK. Forty-four chickens showing TVP-compatible gross lesions were classified into three groups based on the histological lesions: (i) TVP-affected chickens: lymphocytic infiltration and glandular necrosis (n = 15); (ii) lymphocytic proventriculitis (LP)-affected chickens: lymphocytic infiltration without necrosis (n = 18); and (iii) without proventriculitis (WP): no lymphocytic infiltration or necrosis (n = 11). Nine proventriculi (seven out of 15 corresponding to TVP, and two out of 11 corresponding to LP) were positive for CPNV by reverse transcriptase polymerase chain reaction (RT-PCR). These results support the previously suggested idea of CPNV as causative agent of TVP. Moreover, these data show that CPNV can also be detected in a number of cases with LP, which do not fulfil the histological TVP criteria. Phylogenetic analysis of partial sequences of gene VP1 showed that British CPNV sequences were closer to other European CPNV sequences and might constitute a different lineage from the American CPNV. TVP cases with negative CPNV PCR results may be due to chronic stages of the disease or to the reduced PCR sensitivity on formalin-fixed paraffin-embedded tissues. However, involvement of other agents in some of the cases cannot totally be ruled out. As far as the authors are aware, this is the first peer-reviewed report of TVP as well as of CPNV in the UK, and the first exploratory CPNV phylogenetic study.